AWM
IBRX icon

Apollon Wealth Management’s ImmunityBio IBRX Stock Holding History

Apollon Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
+14,867
New +$113K ﹤0.01% 1519
2023
Q2 		– Sell
-13,600
Closed -$24.8K – 965
2023
Q1 		$24.8K Buy
+13,600
New +$42.3K ﹤0.01% 856

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Apollon Wealth Management's IBRX Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in ImmunityBio (IBRX) in Q2 2026: 14,867 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #1519 among its holdings. This is a return to the name: Apollon Wealth Management previously reported a position in IBRX as recently as Q1 2023.

Apollon Wealth Management first reported a position in IBRX in Q1 2023 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Apollon Wealth Management held 14,867 shares of ImmunityBio worth $130K as of Q2 2026.
  • ImmunityBio was a new Apollon Wealth Management position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1519 holding.
  • Apollon Wealth Management first reported a position in ImmunityBio in Q1 2023 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.